ERBB2阳性乳腺癌化疗前瘤内树突状细胞改变肿瘤微环境:一项非随机临床试验
这项单中心1期非随机临床试验在12例早期ERBB2阳性乳腺癌患者中评估瘤内注射cDC1联合ERBB2靶向治疗后再行化疗的安全性和免疫原性,两个剂量组各6例。DL2与血中抗ERBB2 CD4 Th1反应减弱及瘤内先天和适应性反应增加相关,9例客观缓解,7例病理完全缓解,DL2被选为2期剂量。
要点
- 瘤内cDC1联合曲妥珠单抗/帕妥珠单抗在化疗前耐受良好,不良反应可控。
- DL2组血中抗ERBB2 CD4 Th1反应减弱,瘤内先天和适应性反应增加。
- 9例客观缓解(6例部分缓解、3例完全缓解),7例病理完全缓解,DL2被选为2期剂量。
核心结论
- 在非随机临床试验中,新辅助化疗前加入瘤内cDC1和曲妥珠单抗/帕妥珠单抗耐受良好,不良反应可控。
- 基于安全性和免疫原性,DL2被选为2期剂量。
研究设计与样本
- 单中心2期试验的1期导入阶段,非随机临床试验,在Moffitt癌症中心开展。
- 2021年10月至2022年10月入组,2023年分析数据。
- 纳入肿瘤≥1 cm的早期ERBB2阳性乳腺癌患者,共12例接受治疗,DL1和DL2各6例。
- 干预包括瘤内cDC1每周6次,随后紫杉醇80 mg/m2静脉每周12次,曲妥珠单抗(负荷8 mg/kg,后6 mg/kg)和帕妥珠单抗(负荷840 mg,后420 mg)静脉每3周1次共6周期,从cDC1注射第1天开始。
- 主要结局为安全性和免疫反应,次要结局为乳腺MRI和手术残余肿瘤负荷评估的抗肿瘤疗效。
主要发现
- 12例患者中激素受体阳性9例、阴性3例,临床I期5例、II期4例、III期3例。
- cDC1最常见不良事件为1-2级寒战(50%)、疲乏(41.7%)、头痛(33%)和注射部位反应(33%)。
- DL2与血中抗ERBB2 CD4辅助性T细胞1反应减弱相关,同时瘤内先天和适应性反应增加。
- 免疫治疗前后乳腺MRI显示9例客观缓解,其中6例部分缓解、3例完全缓解,3例疾病稳定。
- 手术后7例达到病理完全缓解。
关键数值与推荐
- 紫杉醇剂量80 mg/m2静脉每周12次;曲妥珠单抗负荷8 mg/kg后6 mg/kg;帕妥珠单抗负荷840 mg后420 mg,每3周1次共6周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current chemotherapy regimens for patients with ERBB2 (formerly HER2)-positive breast cancer are associated with considerable morbidity. These patients may benefit from more effective and less toxic therapies. OBJECTIVE: To evaluate the safety, immunogenicity, and preliminary efficacy of intratumoral (IT) delivery of conventional type 1 dendritic cells (cDC1) in combination with ERBB2-targeted therapies. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 (lead-in phase of a single-center phase 2 trial) nonrandomized clinical trial was conducted at Moffitt Cancer Center (Tampa, Florida). Patients were enrolled from October 2021 to October 2022. Data were analyzed in 2023 Patients with early-stage ERBB2-positive breast cancer with tumors 1 cm or larger were eligible. INTERVENTIONS: Treatment included IT delivery of cDC1, 6 times weekly, followed by paclitaxel, 80 mg/m2, intravenously, 12 times weekly. Trastuzumab (8 mg/kg loading dose, then 6 mg/kg) and pertuzumab (840 mg loading dose, then 420 mg) were administered intravenously every 3 weeks for 6 cycles starting from day 1 of cDC1 injections. Two dose levels (DLs) of IT cDC1 (DL1 = 50 million and DL2 = 100 million cells) were evaluated, including 6 patients in each DL. MAIN OUTCOMES AND MEASURES: The primary outcomes were the safety and immune response, and the secondary outcomes were the antitumor efficacy as measured by breast magnetic resonance imaging and residual cancer burden at surgery following neoadjuvant therapy. RESULTS: Twelve ERBB2-positive patients were enrolled and received treatment (DL1 = 6 and DL2 = 6). Nine patients had hormone receptor-positive disease and 3 had hormone receptor-negative disease, with clinical stage I (n = 5), II (n = 4), and III (n = 3). The most frequently observed adverse events with cDC1 were grade 1 to 2 chills (50%), fatigue (41.7%), headache (33%), and injection site reactions (33%). DL2 was associated with a diminished anti-ERBB2 CD4 T-helper 1 blood response with a concomitant increase in innate and adaptive responses within the tumor. Preimmunotherapy and postimmunotherapy breast magnetic resonance imaging results showed 9 objective responses, 6 partial responses, 3 complete responses, and 3 stable diseases. Following surgery, 7 patients had a pathologic complete response. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, the addition of IT cDC1 and trastuzumab/pertuzumab before neoadjuvant chemotherapy was well tolerated with manageable adverse effects. Based on safety and immunogenicity, DL2 was selected for the phase 2 dose. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05325632.
引用
- Han HS, Aldrich AL, Garg SK, et al. Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 39636623. doi:10.1001/jamaoncol.2024.5371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。